As expected, the lactate-treatment group showed remarkably reduced numbers of tumor-infiltrating CD8+ T cells in comparison with the control group, while the proportions of other immune cell subsets remained relatively unchanged (Figure S2K-T). The gene discussed is CD8A; the disease is neoplasm.